임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 24-06-18 09:28
논문번호 301
논문제목(영문) Three-year clinical outcomes of a thin-strut biodegradable-polymer everolimus-eluting stent in patients with acute coronary syndrome.
국내외구분 국내 SCI여부 SCI(E)
연구책임자역할 교신저자
주저자명 Sim DS
교신저자명 Jeong MH
공동저자명 Hyun DY, Cho KH, Kim MC, Hong YJ, Kim JH, Ahn Y, Chun KJ, Ahn TH, Jeong YH, Hwang KK, Lee HC, Park KH, Hwang JY, Lee SU, Cho YK, Park JS, Kim DI, Cho JM, Cho JH, Kim HY, Hwang BH, Kim SH, Yoon MH, Heo JH, Kim SJ, Joo SJ, Bae JH
게제년월일 2023-01-01
ISSN 2799-6999
Impact Factor 0
학술지명 J Cardiovasc Interv
서지사항 0집 / 2권 / 1호,   페이지(19 - 30)
요약초록문
(Abstract) 입력		 Background: This study aimed to investigate safety and efficacy of a thin-strut biodegradable polymer everolimus-eluting stent (BP-EES) (SYNERGYTM; Boston Scientific) in Korean patients with acute coronar y syndrome (ACS).

Methods: From 2016 to 2018, 922 patients with ACS undergoing percutaneous coronary inter vention with SYNERGY were enrolled from 22 hospitals in this single-arm, multicenter, obser vational study. The primar y end point was a patient-oriented composite outcome (POCO), a composite of all-cause death, myocardial infarction (MI), stroke, and any repeat revascularization at 3 years. The key secondar y end point was a device-oriented composite outcome (DOCO), a composite of cardiovascular death, target-vessel MI, and target lesion revascularization at 3 years.

Results: A total of 788 patients who completed 3-year follow-up were analyzed. The mean age was 63 ± 11 years, 75% were men, 60% had acute MI, 52% hypertension and 31% diabetes. Transradial PCI was performed in 68%; multivessel PCI in 21%; and intravascular ultrasound imaging in 34%. The number of stents, stent diameter, and stent length per patient were 1.4 ± 0.7, 3.1 ± 0.5 mm, and 36.5 ± 22.8 mm, respectively. All-cause mortality was 1.1% at 1 year and 3.8% at 3 years. POCO occurred in 6.2% at 1 year and in 9.9% at 3 years. DOCO occurred in 2.8% at 1 year and in 3.6% at 3 years. Definite or probable stent thrombosis (ST) developed in 2 patients (0.3%, 1 subacute ST, 1 ver y late ST).

Conclusions: The thin-strut BP-EES showed excellent safety and efficacy in real-world Korean patients with ACS at 3-year follow-up.
파일  C 301.pdf (2.5M) DATE : 2024-06-18 09:28:09